JOURNAL OF ISOTOPES

Previous Articles     Next Articles

Progress of Preparation and Applications of No-Carrier-Added Radioiodinated MIBG

FAN Cai-yun;DENG Xin-rong;LUO Zhi-fu   

  1. China Institute of Atomic Energy, Beijing 102413, China
  • Online:2017-02-20 Published:2017-03-06

无载体放射性碘标记间碘苄胍的制备和应用研究进展

樊彩云;邓新荣;罗志福   

  1. 中国原子能科学研究院,北京102413

Abstract:

Radioiodinated metaiodobenzylguanidine (MIBG) is an important diagnostic agent for oncology and cardiology, or as a targeted radiotherapeutic for neuroendocrine tumors. Commercial formulations of radioiodinated MIBG (carrier-added (c.a.) [*I]MIBG) contain large mass amount of unlabeled MIBG, which is disadvantage to diagnosis or therapy with adverse effects in patients. High specific activity no-carrier-added radioiodinated MIBG ( n.c.a. [*I]MIBG) has the advantage of lower risk of adverse effects and is more suitable for clinical diagnostic and therapy. Much importance was attached to the preparation and application of n.c.a. [*I]MIBG, and great achievements had been made in the last 20 years. Here we considered the methods of preparation of n.c.a.[*I]MIBG, comparison of n.c.a. [*I]MIBG and c.a. [*I]MIBG in diagnostic and therapy, and the clinical status of n.c.a. [*I]MIBG.

Key words: meta-iodobenzylguanidine, no-carrier-added, high specific activity, diagnostic, radiotherapy

摘要:

放射性碘标记间碘苄胍([*I]MIBG)在神经内分泌肿瘤和心脏病的诊断,以及神经内分泌肿瘤的治疗方面起着重要作用。高比活度无载体放射性碘标记MIBG(no-carrier-added (n.c.a.) [*I]MIBG)克服了目前商用放射性碘标记MIBG(carrier-added(c.a.) [*I]MIBG)的缺点,有利于临床使用。近20年来,无载体放射性碘标记MIBG的制备和应用研究逐渐得到重视,并取得了重要进展。本文对无载体放射性碘标记MIBG的制备方法进行了总结,对n.c.a. [*I]MIBG和c.a. [*I]MIBG诊断与治疗方面的特点进行了对比,同时介绍了其在临床研究方面的最新进展。

关键词: 间碘苄胍, 无载体, 高比活度, 诊断, 放射性治疗